- Home
- APD vs REGN Comparison
APD vs REGN Comparison
Compare APD & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APD | REGN |
|---|---|---|
| Founded | 1940 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.6B | 79.4B |
| IPO Year | 1994 | 1995 |
Fundamental Metrics
Financial Performance| Metric | APD | REGN |
|---|---|---|
| Price | $295.24 | $752.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 24 |
| Target Price | $294.00 | ★ $819.54 |
| AVG Volume (30 Days) | ★ 1.4M | 559.3K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.49% | 0.50% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | 3.04 | ★ 41.48 |
| Revenue | ★ $12,037,300,000.00 | $5,872,227,000.00 |
| Revenue This Year | $5.74 | $11.69 |
| Revenue Next Year | $6.07 | $10.06 |
| P/E Ratio | $95.32 | ★ $17.98 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $229.11 | $476.49 |
| 52 Week High | $301.11 | $821.11 |
Technical Indicators
Market Signals| Indicator | APD | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 69.02 | 44.98 |
| Support Level | $277.75 | $740.39 |
| Resistance Level | $298.43 | $788.69 |
| Average True Range (ATR) | 5.78 | 21.27 |
| MACD | 0.93 | -3.59 |
| Stochastic Oscillator | 93.28 | 19.64 |
Price Performance
Historical ComparisonAbout APD Air Products and Chemicals Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the world's largest supplier of hydrogen and helium. It has a unique portfolio serving customers across industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated roughly $12 billion in revenue in fiscal 2025.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).